Denali Therapeutics Inc. (DNLI) is a Healthcare stock trading at $24.96 (as of 2026-08-20), with a market capitalization of $3.99B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Denali Therapeutics is a biopharmaceutical company developing drug candidates for neurodegenerative diseases, including a leucine-rich repeat kinase 2 (LRRK2) inhibitor program for Parkinson's disease (BIIB122/DNL151), and additional early-stage candidates for Hunter syndrome (DNL310) and amyotrophic lateral sclerosis (ALS) (DNL343), with clinical development currently underway in Phase I, Phase Ib, and Phase I/II studies.
Denali's path to profitability is driven by clinical success, because its key therapeutic candidates are in early clinical phases, meaning future commercial value depends on whether these trials produce the safety and efficacy outcomes required for advancement and regulatory approval.
Business quality (Weak): The company has multiple early-stage programs across neurodegenerative-related indications, and the provided operating updates focus on trial enrollment and biomarker activity, but there is no segment breakdown or mature product performance data included here.
| Price | $24.96 |
| Market Cap | $3.99B |
| Price / Book | 4.78 |
| Price / Sales | 1107.05 |
| FCF Yield | -10.5% |
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | 142.5% |
| FCF Growth (YoY) | -2.0% |
| Altman Z-Score | 14.85 (safe) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | BlackRock, Inc. ($250.26M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Ryan J. Watts |
| Employees | 443 |
| Country | US |
| IPO Date | 2017-12-08 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.